SavedAdd your journal

Journals / Turkish Journal of Hematology / 2012 / Cilt: 29 - Sayı: 1

Lösemili hastalarda c-kit geni ekson 11 mutasyonlarının sıklığı

The frequency of mutations in exon 11 of the c-kit gene in patients with leukemia

Syed Rizwan HUSSAIN
G. Sunil BABU
Hena NAQVI
Pradyumn SINGH
Farzana MAHDI
Pages
10–16
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: The results suggest that mutations in exon 11 of the c-kit gene might be useful as molecular genetic markers for leukemia

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To determine the frequency of mutations in exon 11 of the c-kit gene in patients with leukemia.
📊
Key Findings & Data:Material and Methods: The study included 50 leukemia patients (31 with acute myeloid leukemia, 5 with acute lymphoblastic leukemia, 9 with chronic myeloid leukemia, and 5 with chronic lymphocytic leukemia) that underwent PCR-SSCP, followed by direct DNA sequencing.
💡
Conclusion & Impact:Conclusion: The results suggest that mutations in exon 11 of the c-kit gene might be useful as molecular genetic markers for leukemia
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: To determine the frequency of mutations in exon 11 of the c-kit gene in patients with leukemia. Material and Methods: The study included 50 leukemia patients (31 with acute myeloid leukemia, 5 with acute lymphoblastic leukemia, 9 with chronic myeloid leukemia, and 5 with chronic lymphocytic leukemia) that underwent PCR-SSCP, followed by direct DNA sequencing. Results: In all, 28 of the leukemia patients were male and 22 were female, with a mean age of 31.88 years (range: 2-65 years). In total, 20 mutations in 19 patients were identified, including Lys550Asn, Tyr568Ser, Ile571Thr, Thr574Pro, Gln575His, Tyr578Pro, Asp579His, His580Gln, Arg586Thr, Asn587Asp, and Arg588Met, as well as novel point mutations at codons Ile563Lys, Val569Leu, Tyr570Ser, and Pro577Ser. Ile571Leu substitution was observed in 2 patients and Trp582Ser substitution was observed in 3 patients. Conclusion: The results suggest that mutations in exon 11 of the c-kit gene might be useful as molecular genetic markers for leukemia

Özet

Amaç: Lösemili hastalarda c-kit geni ekson 11 mutasyonlarının sıklığını belirlemek. Gereç ve Yöntemler: Bu çalışma PCR-SCCP ve sonrasında direkt DNA sekanslama yapılan 50 lösemi hastası (31 akut myeloid lösemi, 5 akut lenfoblastik lösemi, 9 kronik myeloid lösemi ve 5 kronik lenfositik lösemi) hastası ile yapıldı. Bulgular: Genel olarak lösemi hastalarının 28’i erkek ve 22’si kadındı ve ortalama yaş 31,88 (aralık: 2-65) yıldı. Toplam olarak 19 hastada Lys550Asn, Tyr568Ser, Ile571Thr, Thr574Pro, Gln575His, Tyr578Pro, Asp579His, His580Gln, Arg586Thr, Asn587Asp ve Arg588Met ve ayrıca Ile563Lys, Val569Leu, Tyr570Ser ve Pro577Ser kodonlarında yeni nokta mutasyonları olmak üzere 20 mutasyon saptandı. Ile571Leu yerine konması 2 hastada ve Trp582Ser yerine konması 3 hastada görüldü. Sonuç: Sonuçlar c-kit geni ekson 11 mutasyonlarının lösemi için moleküler genetik işaretler olarak faydalı olabileceğini düşündürmektedir.

🔖

Cite This Article

HUSSAIN, S. R., BABU, G. S., NAQVI, H., SINGH, P., MAHDI, F. (2012). Lösemili hastalarda c-kit geni ekson 11 mutasyonlarının sıklığı. Turkish Journal of Hematology, Cilt: 29 - Sayı: 1, 10–16. https://ajindex.com/articles/412607

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Mathers, Colin D, Cynthia Boschi-Pinto, Alan D Lopez and Christopher JL Murray: Cancer incidence, mortality and survival by site for 14 regions of the world. Global Programme on Evidence for Health Policy Discussion 2001; Paper No. 13 (World Health Organization
  2. Rowley JD: Identification of a translocation with quinacrine fluorescence in a patient with acute leukemia. Ann Genet 1973; 16: 109-112 3. Reilly JT: Class III receptor tyrosine kinases: Role in leukaemogenesis. Br J Haematol 2002; 116: 744-757 4. Reuss-Borst MA, Buhring HJ, Schmidt H, Muller CA: AML: Immunophenotypic heterogeneity and prognostic significance of c-kit expression. Leukemia 1994; 8: 258-263 5. Cole SR, Aylett GW, Harvey NL, Cambareri AC, Ashman LK: Increased expression of c-Kit or its ligand Steel Factor is not a common feature of adult acute myeloid leukaemia. Leukemia 1996; 10: 288-296 6. Higuchi M, O’Brien D, Kumaravelu P, Lenny N, Yeoh EJ, Downing JR: Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell 2002; 1: 63-74 7. Kelly LM, Kutok JL, Williams IR, Boulton CL, Amaral SM, Curley DP, Ley TJ, Gilliland DG: PML/RARalpha and FLT3- ITD induce an APL-like disease in a mouse model. Proc Natl Acad Sci USA 2002; 99: 8283-8288 8. Zhao M, Kiyoi H, Yamamoto Y, Ito M, Towatari M, Omura S, Kitamura T, Ueda R, Saito H, Naoe T: In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor. Leukemia 2000; 14: 374-378 9. Tse KF, Novelli E, Civin CI, Bohmer FD, Small D: Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor. Leukemia 2001; 15: 1001-1010 10. Levis M, Tse KF, Smith BD, Garrett E, Small D: A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood 2001; 98: 885-887 11. Ihle JN, Witthuhn BA, Quelle FW, Yamamoto K, Silvennoinen O: Signaling through the hematopoietic cytokine receptors. Annu Rev Immunol 1995; 13: 369-398 12. Ullrich A, Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 1990; 61: 203-212 13. Matthews W, Jordan CT, Wiegand GW, Pardoll D, Lemischka IR: A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell 1991; 65: 1143-1152 14. Rosnet O, Schiff C, Pébusque MJ, Marchetto S, Tonnelle C, Toiron Y, Birg F, Birnbaum D: Human FLT3/FLK